JOUNCE THERAPEUTICS, INC.
CIK 0001640455
Revenue (TTM)
—
FY Mar 2023
Net Income (TTM)
−$131.97M
+44.0% YoY
FY Mar 2023
EPS Diluted (TTM)
−$2.56
+45.6% YoY
FY Mar 2023
Gross Margin
—
FY Mar 2023
Operating Margin
—
FY Mar 2023
Net Margin
—
FY Mar 2023
Free Cash Flow (TTM)
−$113.87M
FY Mar 2023
Cash
$150.57M
FY Mar 2023
Total Debt
—
FY Mar 2023
Shares Outstanding
52.64M sh
FY Mar 2023
Revenue & Net Income
EPS (Diluted)
Cash Flow
Revenue Growth (YoY)
No data available for this metric.